FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283710810> ?p ?o ?g. }

• W4283710810 endingPage "1509" @default.
• W4283710810 startingPage "1509.1" @default.
• W4283710810 abstract "Background The main goal of “T2T” strategy for spondyloarthritis (SpA) is to achieve clinical remission or inactive disease. In 2001, the ASAS formulated criteria for partial remission [1], and the Russian Expert Group for Study of SpA (ExSpA) in 2018 identified clinical-laboratory remission (absence of clinical manifestations of the disease that persists for 6 months with normal values ​​of CRP and ESR) [2]. Objectives to analyze the therapy in patients with early axial spondyloarthritis who achieved the ASAS partial remission and the clinical-laboratory remission at the 3rd year of follow-up. Methods The study included patients with early axSpA (ASAS criteria 2009 with inflammation back pain duration less than 5 years) from the CORSAR cohort (Cohort of Early SpondyloArthritis), formed at the V.A. Nasonova Research Institute of Rheumatology. The cohort includes 175 patients with axSpA. The analysis included 66 patients followed for at least 3 years, of which 37 (56%) were men. The average age of patients was 31.5 (5.7) years, the average duration of the disease was 22.1 (17.0) months, 63 (95.4%) patients were HLA B27 positive. The criteria for clinical-laboratory remission include the following indicators (at least during 6 month): ASDAS≤1,3, BASDAI ≤1,0, morning stiffness<30 min., absence of swollen joints, absence of enthesitis, nocturnal pain ≤1,0 (NRS), spinal pain≤1,0 (NRS), no active extra-articular manifestations, normal levels of CRP and ESR [2]. The criteria for ASAS partial remission include a value not above 2 units in each of the 4 domains: patient global, pain, function, inflammation [1]. Results Initially, no patients met the ASAS partial remission and the clinical-laboratory remission criteria. By the 3rd year of follow-up, the clinical-laboratory remission was achieved by 21 (31.8%) patients; the ASAS partial remission - 29 (44.0%) patients. When analyzing therapy at the 3rd year of follow-up of patients with early axSpA who achieved the clinical-laboratory and the ASAS partial remission, it was revealed that patients more often achieved remission when taking NSAIDs, a quarter of patients achieved remission on combined therapy with biologics and NSAIDs (Table 1). It is noting that a quarter of patients canceled therapy on their own. Table 1. Therapy of patients with axSpA who achieved the clinical-laboratory and the ASAS partial remission at 3 years of follow-up. The ASAS partial remission (n=29) The clinical-laboratory remission (n=21) p NSAIDs, n (%) 14 (48,2%) 9 (42,8%) р>0,05 NSAIDs+sulfasalazine, n (%) 0 1 (4,7%) р>0,05 Biologics, n (%) 2 (6,8%) 0 р>0,05 Biologics+NSAIDs, n (%) 6 (20,6%) 5 (23,8%) р>0,05 Biologics+sulfasalazine, n (%) 0 1 (4,7%) р>0,05 Biologics+sulfasalazine+NSAIDs, n (%) 1 (3,4%) 0 р>0,05 Without therapy, n (%) 6 (20,6%) 5 (23,8%) р>0,05 Conclusion 1. In the 3d year of follow-up 32% of patients with early axSpA achieved the clinical-laboratory remission and 44% - of the ASAS partial remission. 2. More than 40% of patients with early axSpA achieved remission while taking NSAIDs. References [1]Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. [2]Gaidukova I.Z., Rebrov A.P., Korotaeva T.V., Dubinina T.V., Otteva E.N., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.I., Ivanova O.N., Lapshina S.A., Nesmeyanova O.B., Nikishina I.P., Raskina T.A., Rumyantseva O.A., Smirnov A.V., Sitalo A.V., Erdes S.F. REMISSION IN AXIAL SPONDYLOARTHRITIS: DEFINITION AND EVALUATION TOOLS (RECOMMENDATIONS OF THE SPONDYLOARTHRITIS STUDY GROUP OF EXPERTS, ALL-RUSSIAN PUBLIC ORGANIZATION «THE ASSOCIATION OF RHEUMATOLOGY OF RUSSIA»). Rheumatology Science and Practice. 2018;56(1):10-14. (In Russ.) https://doi.org/10.14412/1995-4484-2018-10-14 Disclosure of Interests None declared" @default.
• W4283710810 created "2022-06-30" @default.
• W4283710810 creator A5020386462 @default.
• W4283710810 creator A5051801009 @default.
• W4283710810 creator A5064806859 @default.
• W4283710810 creator A5079490303 @default.
• W4283710810 creator A5087826419 @default.
• W4283710810 date "2022-05-23" @default.
• W4283710810 modified "2023-09-27" @default.
• W4283710810 title "AB0765 Analysis of therapy in patients with early axial spondyloarthritis who achieved the ASAS partial remission and the clinical-laboratory remission at the 3rd year of follow-up" @default.
• W4283710810 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3020" @default.
• W4283710810 hasPublicationYear "2022" @default.
• W4283710810 type Work @default.
• W4283710810 citedByCount "0" @default.
• W4283710810 crossrefType "journal-article" @default.
• W4283710810 hasAuthorship W4283710810A5020386462 @default.
• W4283710810 hasAuthorship W4283710810A5051801009 @default.
• W4283710810 hasAuthorship W4283710810A5064806859 @default.
• W4283710810 hasAuthorship W4283710810A5079490303 @default.
• W4283710810 hasAuthorship W4283710810A5087826419 @default.
• W4283710810 hasBestOaLocation W42837108101 @default.
• W4283710810 hasConcept C126322002 @default.
• W4283710810 hasConcept C141071460 @default.
• W4283710810 hasConcept C1862650 @default.
• W4283710810 hasConcept C198451711 @default.
• W4283710810 hasConcept C2776260265 @default.
• W4283710810 hasConcept C2777077863 @default.
• W4283710810 hasConcept C2777453003 @default.
• W4283710810 hasConcept C2780131103 @default.
• W4283710810 hasConcept C71924100 @default.
• W4283710810 hasConcept C72563966 @default.
• W4283710810 hasConcept C90924648 @default.
• W4283710810 hasConceptScore W4283710810C126322002 @default.
• W4283710810 hasConceptScore W4283710810C141071460 @default.
• W4283710810 hasConceptScore W4283710810C1862650 @default.
• W4283710810 hasConceptScore W4283710810C198451711 @default.
• W4283710810 hasConceptScore W4283710810C2776260265 @default.
• W4283710810 hasConceptScore W4283710810C2777077863 @default.
• W4283710810 hasConceptScore W4283710810C2777453003 @default.
• W4283710810 hasConceptScore W4283710810C2780131103 @default.
• W4283710810 hasConceptScore W4283710810C71924100 @default.
• W4283710810 hasConceptScore W4283710810C72563966 @default.
• W4283710810 hasConceptScore W4283710810C90924648 @default.
• W4283710810 hasIssue "Suppl 1" @default.
• W4283710810 hasLocation W42837108101 @default.
• W4283710810 hasOpenAccess W4283710810 @default.
• W4283710810 hasPrimaryLocation W42837108101 @default.
• W4283710810 hasRelatedWork W1488490750 @default.
• W4283710810 hasRelatedWork W2052498720 @default.
• W4283710810 hasRelatedWork W2193802385 @default.
• W4283710810 hasRelatedWork W2332395105 @default.
• W4283710810 hasRelatedWork W2379622864 @default.
• W4283710810 hasRelatedWork W2408979496 @default.
• W4283710810 hasRelatedWork W2554098103 @default.
• W4283710810 hasRelatedWork W2887824106 @default.
• W4283710810 hasRelatedWork W3163961032 @default.
• W4283710810 hasRelatedWork W3180393573 @default.
• W4283710810 hasVolume "81" @default.
• W4283710810 isParatext "false" @default.
• W4283710810 isRetracted "false" @default.
• W4283710810 workType "article" @default.